Abbott and AstraZeneca Extend Relationship to Include Co-Promotion of TRILIPIX®

News   Jun 16, 2009

 
Abbott and AstraZeneca Extend Relationship to Include Co-Promotion of TRILIPIX®
 
 
 

RELATED ARTICLES

Protein "Intentionally" Terminates own Synthesis by Destabilizing Synthesis Machinery — the Ribosome

News

A research group has discovered that a protein, during its synthesis, may destabilize the structure of the ribosome and end its own synthesis prematurely, and found that this phenomenon is used for adapting the cell to its environment.

READ MORE

Novel Chemistry Technique Simplifies Late-Stage Modification of Drug Compounds

News

Chemists at The Scripps Research Institute (TSRI) have invented a technique that overcomes a long-standing problem in organic chemistry and should streamline the process of discovery and development for many new drugs.

READ MORE

Advanced Prostate Cancer: EMA Approves Abiraterone Combined With Hormone Therapy as First-line Treatment

News

The prostate cancer drug abiraterone has been approved by the European Medicines Agency in combination with standard hormone therapy for use as a first-line treatment for advanced prostate cancer.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE